Loading
POLE2 (DNA polymerase epsilon subunit 2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma, Leukaemia, Lung cancer and 5 more.
Accessory component of the DNA polymerase epsilon complex. Participates in DNA repair and in chromosomal DNA replication.
Open Targets scores its association with cancer at 0.64 (direct and indirect evidence; datatypes literature 0.93, animal model 0.43, genetic association 0.00, clinical 0.99).
In plain words · POLE2 (DNA polymerase epsilon subunit 2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma, Leukaemia, Lung cancer and 5 more.
POLE2 (DNA polymerase epsilon subunit 2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma, Leukaemia, Lung cancer and 5 more.
Accessory component of the DNA polymerase epsilon complex. Participates in DNA repair and in chromosomal DNA replication.
No product in this corpus aims at POLE2 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Broadly expressed or essential: HPA lists POLE2 among essential proteins; a medicine acting on the wild-type protein would expose normal tissue too. HPA POLE2: RNA tissue enhanced (bone marrow 17 nTPM); no normal tissue stained high. Distribution: 6 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Lymphoma, Leukaemia, Lung cancer (all types), Myeloid neoplasms, Breast cancer (all types), Ovarian cancer); Open Targets associates it with 10 specific cancer types at or above 0.5 (acute lymphoblastic leukemia, non-small cell lung carcinoma, B-cell chronic lymphocytic leukemia, acute myeloid leukemia, exocrine pancreatic carcinoma, ovarian carcinoma and more). (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas POLE2 tissue; Open Targets ENSG00000100479 associations
First described 1997. Earliest sequence paper UniProt cites for the protein: Li et al, J. Biol. Chem, 1997, "Purification, cDNA cloning, and gene mapping of the small subunit of human DNA polymerase epsilon". Source.
Sources: HGNC HGNC:9178 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P56282 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000100479 (association with cancer (MONDO_0004992) 0.64; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.60, ovarian cancer 0.58, acute myeloid leukaemia 0.59, acute lymphoblastic leukaemia 0.60, B-cell chronic lymphocytic leukaemia 0.59, non-Hodgkin lymphoma 0.61 (GraphQL API, CC0))
Accessory component of the DNA polymerase epsilon complex. Participates in DNA repair and in chromosomal DNA replication. Location: Nucleus (UniProt). Locus 14q21.3 (HGNC).
RNA: tissue enhanced (bone marrow 17 nTPM), detected in many normal tissues.
No normal tissue stained high.
No cancer stained high; medium in breast cancer, colorectal cancer, endometrial cancer, head and neck cancer.
HPA POLE2 tissue · HPA POLE2 pathology · HPA protein class: Essential proteins, FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"POLE2" OR ABSTRACT:"POLE2" OR TITLE:"DNA polymerase epsilon 2, accessory subunit" OR ABSTRACT:"DNA polymerase epsilon 2, accessory subunit" OR TITLE:"DNA polymerase epsilon subunit 2" OR ABSTRACT:"DNA polymerase epsilon subunit 2" OR TITLE:"DPE2" OR ABSTRACT:"DPE2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about POLE2, not a curated reading list.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.